These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 9702690)
1. A Japanese family with adrenoleukodystrophy with a codon 291 deletion: a clinical, biochemical, pathological, and genetic report. Kano S; Watanabe M; Kanai M; Koike R; Onodera O; Tsuji S; Okamoto K; Shoji M J Neurol Sci; 1998 Jun; 158(2):187-92. PubMed ID: 9702690 [TBL] [Abstract][Full Text] [Related]
2. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548 [TBL] [Abstract][Full Text] [Related]
3. Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy. Duchesne N; Dufour M; Bouchard G; Grondin P; Lemieux B Can Assoc Radiol J; 1995 Oct; 46(5):386-91. PubMed ID: 7552831 [TBL] [Abstract][Full Text] [Related]
4. Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review. Ogaki K; Koga S; Aoki N; Lin W; Suzuki K; Ross OA; Dickson DW Neuropathology; 2016 Feb; 36(1):64-76. PubMed ID: 26227820 [TBL] [Abstract][Full Text] [Related]
5. The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo's oil. Suzuki Y; Imamura A; Shimozawa N; Kondo N Brain Dev; 2001 Mar; 23(1):30-3. PubMed ID: 11226726 [TBL] [Abstract][Full Text] [Related]
6. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Moser HW; Raymond GV; Lu SE; Muenz LR; Moser AB; Xu J; Jones RO; Loes DJ; Melhem ER; Dubey P; Bezman L; Brereton NH; Odone A Arch Neurol; 2005 Jul; 62(7):1073-80. PubMed ID: 16009761 [TBL] [Abstract][Full Text] [Related]
7. [Adrenomyeloneuropathy: a form of X-linked adrenoleukodystrophy. Report of a family]. Rzeski M; Kuran W; Mierzewska H; Vreken P; Wanders RJ; Zaremba J Neurol Neurochir Pol; 1999; 33(5):1173-85. PubMed ID: 10672567 [TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics of X-linked adrenoleukodystrophy]. Xiong H; Zhang YH; Qin J; Xiao JX; Shi CY; Zhou SM; Wu XR Zhonghua Er Ke Za Zhi; 2003 Mar; 41(3):203-7. PubMed ID: 14756960 [TBL] [Abstract][Full Text] [Related]
11. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542 [TBL] [Abstract][Full Text] [Related]
12. MR spectroscopic imaging of normal-appearing white matter in adrenoleukodystrophy. Izquierdo M; Adamsbaum C; Benosman A; Aubourg P; Bittoun J Pediatr Radiol; 2000 Sep; 30(9):621-9. PubMed ID: 11009301 [TBL] [Abstract][Full Text] [Related]
13. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. van Geel BM; Bezman L; Loes DJ; Moser HW; Raymond GV Ann Neurol; 2001 Feb; 49(2):186-94. PubMed ID: 11220738 [TBL] [Abstract][Full Text] [Related]
14. Adrenoleukodystrophy in a Chinese boy. Wong V Brain Dev; 1992 Jul; 14(4):276-7. PubMed ID: 1279999 [TBL] [Abstract][Full Text] [Related]
15. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Moser HW J Neuropathol Exp Neurol; 1995 Sep; 54(5):740-5. PubMed ID: 7666063 [TBL] [Abstract][Full Text] [Related]
16. Therapy of X-linked adrenoleukodystrophy. Semmler A; Köhler W; Jung HH; Weller M; Linnebank M Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549 [TBL] [Abstract][Full Text] [Related]